What Happened?
San Francisco, CA-based Gritstone oncology Appointed Andrew Allen as Chief Executive Officer
About the Company
Gritstone Oncology is a privately-held company headquartered in the San Francisco Bay Area with key functions located in Cambridge, Massachusetts and Pleasanton, California. We launched in October 2015, and since inception, have successfully raised two large, private financing rounds. We currently employ more than 60 professionals. We have brought together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics and immunotherapy. With our unique approach to immuno-oncology, we are developing next-generation personalized immunotherapies to fight cancer in patients with the most difficult-to-treat tumors. We plan to combine these personalized neoantigen-targeted therapies with current immune checkpoint modulatory approaches to improve response rates and survival in patients with solid tumors.
About the Person
Andrew Allen, M.D., Ph.D., President and Chief Executive Officer Andrew Allen is a Co-Founder of Gritstone Oncology and serves as President, Chief Executive Officer and a member of the Board of Directors. Dr. Allen was a Co-Founder of Clovis Oncology and served as Executive Vice President of Clinical and Pre-Clinical Development and Chief Medical Officer from the time of the company`s inception in 2009 until July 2015. Prior to that, Allen was Chief Medical Officer at Pharmion Corporation, which was sold to Celgene Corporation in 2008 for $2.9 billion, following the development of Vidaza for the treatment of myelodysplastic syndromes and Thalomid for the front-line treatment of multiple myeloma. Allen also served previously in Clinical Development leadership roles at Chiron Corporation and Abbott Laboratories, and worked at McKinsey & Company in London and New Jersey, advising life science companies on strategic issues. Allen trained in Medicine at Oxford University and obtained a Ph.D. in Immunology at Imperial College, London. He currently serves on the board of directors of Epizymeand advises Epic Sciences.
Info Source
Press Release
Short Profile